Navigation Links
UBM Medica's ONCOLOGY to Feature Special Content on Role of Genetic Testing in GI Cancers
Date:2/10/2012

NORWALK, Conn., Feb. 10, 2012 /PRNewswire/ -- UBM Medica's ONCOLOGY and CancerNetwork today announced that the April issue will feature insights by physicians from the clinical genetics service at Memorial Sloan-Kettering Cancer Center in which they explain the role of genetic testing in gastrointestinal cancers.

In the article, Kenneth Offit, MD, MPH, and colleagues bring clarity to when, why—and to what end—to refer patients for genetic testing for GI cancers. Using a case-based approach to illustrate what is known and unknown about weak and strong hereditary factors for GI cancers, the authors demonstrate how this knowledge can be used to improve outcomes in those who are predisposed to developing these malignancies.

"While there has been extraordinary attention paid by oncologists ... to inherited breast and ovarian cancer, the syndromes of predisposition to colon, gastric, and other GI cancers are of equal importance," said Dr. Offit, who is currently Chief of the Clinical Genetics Service at Memorial Sloan-Kettering. He noted that although "the genetics of hereditary colon cancer, for example, appears much more complex than breast cancer, as it involves several genes and dominant as well as recessive forms of inheritance," genetic counseling and testing for colon cancer risk has an important advantage: the availability of targeted endoscopic surveillance to remove premalignant lesions. The authors point out that "there are relatively few diseases in which early identification of at-risk individuals can have such dramatic outcomes from primary disease prevention."

The authors include Kasmintan Schrader, MD, Kenneth Offit, MD, MPH, and Zsofia K. Stadler, MD. Dr. Offit is known world-wide for his work in cancer genetics. It was his research group that in 1996 first described the common genetic mutations of the BRCA1 and BRCA2 genes that are associated with increased breast cancer risk.

About UBM Medica

Addressing today's healthcare information needs, UBM Medica, a division of UBM plc (UBM.L), delivers strategic, integrated communications solutions and comprehensive reach—online, in print, live, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, drug databases, data services, live events, and other valuable resources, UBM Medica also delivers comprehensive communication solutions for the pharmaceutical and related industries. US websites include PsychiatricTimes.com, CancerNetwork.com, DiagnosticImaging.com, ConsultantLive.com, OBGYN.net, PhysiciansPractice.com and SearchMedica.com.  Employing more than 1,400 people with offices in 29 countries, UBM Medica is headquartered in London.  For more information, visit http://www.ubmmedica.com/.

Media contact:
Amy Erdman
Director of Marketing
203-523-7041
amy.erdman@ubm.com


'/>"/>
SOURCE UBM Medica
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) today announced that ... Raymond James and Associates, 38 th Annual ... Orlando, FL. Cowen and Company ... March 7, 2017 in Boston, MA. ... in Miami, FL. Individuals ...
(Date:2/27/2017)... February 27, 2017 Leading Countries, Technologies and ... is expected to grow at a CAGR of 8.9% from 2016-2021 ... grow at a CAGR of 9.1% from 2016 to 2027. The ... ... will benefit you Read on to discover how you can ...
(Date:2/27/2017)... – December 2016 Revenues amounted to SEK 0.3 (0.1) ... Result after tax amounted to SEK -16.3 (-6.5) million, corresponding to ... flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... to SEK -39.5 (-29.5) million Result after tax amounted to ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... the lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for ... analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements ...
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... ... 26, 2017 , ... Functional imaging data supports improved cognition ... released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , ... in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
Breaking Medicine News(10 mins):